NOTUM is a potential pharmacodynamic biomarker of wnt pathway inhibition

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12386-12392

  Madan, Babita ^a   Ke, Zhiyuan ^b   Lei, Zheng Deng ^a   Oliver, Frois Ashley ^a   Oshima, Masanobu ^c   Lee, May Ann ^b   Rozen, Steve ^a   Virshup, David M ^a,d  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b Agency for Science   (Singapore)

^c KANAZAWA UNIVERSITY   (Japan)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Notum; PORCN inhibitor; Wnt signaling

Indexed keywords

AXIN2 PROTEIN; BIOLOGICAL MARKER; ESTERASE; NOTUM PROTEIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; AXIN; AXIN2 PROTEIN, HUMAN; ETC-159; FUSED HETEROCYCLIC RINGS; MEMBRANE PROTEIN; NOTUM PROTEIN, HUMAN; PORCN PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; BLOOD ANALYSIS; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SECRETION; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DOWN REGULATION; DRUG EFFECTS; FIBROSARCOMA; GENETIC TRANSFECTION; HUMAN; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; TUMOR CELL LINE; WNT SIGNALING; XENOGRAFT;

ACYLTRANSFERASES; ANIMALS; AXIN PROTEIN; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DOWN-REGULATION; ESTERASES; FIBROSARCOMA; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HETEROGRAFTS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; PANCREATIC NEOPLASMS; TRANSFECTION; WNT SIGNALING PATHWAY;

EID: 84962815291     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7157     Document Type: Article

References (20)

1. Chien AJ, Conrad WH, Moon RT. A Wnt Survival Guide: From Flies to Human Disease. Journal of Investigative Dermatology. 2009; 129:1614-27.
2. Varmus H, Nusse R. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J. 2012; 31:2670-84.
3. Yu J, Virshup DM. Updating the Wnt pathways. Biosci Rep. 2014; 34.
4. Janda CY, Waghray D, Levin AM, Thomas C, Garcia KC. Structural Basis of Wnt Recognition by Frizzled. Science. 2012; 337:59-64.
5. Coombs GS, Yu J, Canning CA, Veltri CA, Covey TM, Cheong JK, Utomo V, Banerjee N, Zhang ZH, Jadulco RC, Concepcion GP, Bugni TS, Harper MK, Mihaleck I, et al. WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification. Journal of Cell Science. 2010; 123:3357-67.
6. Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, Virshup DM. Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary Cancer. Cancer Research. 2013; 73:502-7.
7. Flowers GP, Topczewska JM, Topczewski J. A zebrafish Notum homolog specifically blocks the Wnt/ β-catenin signaling pathway. Development. 2012; 139:2416-25.
8. Zhang X, Cheong S-M, Amado NG, Reis AH, MacDonald BT, Zebisch M, Jones Y, Abreu JG, He X. Notum Is Required for Neural and Head Induction via Wnt Deacylation, Oxidation, and Inactivation. Developmental Cell. 2015; 32:719-30.
9. Giráldez AJ, Copley RR, Cohen SM. HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient. Developmental Cell. 2002; 2:667-76.
10. Kakugawa S, Langton PF, Zebisch M, Howell SA, Chang T-H, Liu Y, Feizi T, Bineva G, O'Reilly N, Snijders AP, Jones EY, Vincent JP Notum deacylates Wnt proteins to suppress signalling activity. Nature. 2015; 519:187-92.
11. Madan B, Ke Z, Harmston N, Yei HS, Frois AO, Alam J, Jeyaraj DA, Pedharkar V, Ghosh K, Virshup IH, Manoharan V, Ong EHQ Sangthongpitag K, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. Oncogene. 2015; 1-33.
12. Coombs GS, Schmitt AA, Canning CA, Alok A, Low ICC, Banerjee N, Kaur S, Utomo V, Jones CM, Pervaiz S, Toone EJ, Virshup DM. Modulation of Wnt/β-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer. Oncogene. 2011; 31:213-25.
13. Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T, Zhang S, Lee M et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013; 145:554-65.
14. Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol. 2012; 47:97-106.
15. Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by β-catenin/TCF. Cancer Sci. 2008; 99:1139-46.
16. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2013; 110:12649-54.
17. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988; 55:619-25.
18. Madan B, Virshup DM. Targeting Wnts at the Source-New Mechanisms, New Biomarkers, New Drugs. Molecular Cancer Therapeutics. 2015; 14:1087-94.
19. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan J, Fisher M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA. 2012; 109:11717-22.
20. Pommier AJC, Shaw R, Spencer SKM, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jüngenssmeier JM. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib. Br J Cancer. 2014; 111:1590-604.